Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 2Diabetes Mellitus, Type 2 2Pulmonary Disease, Chronic Obstructive 1Lung Neoplasms 1Disease 1

Interventions

Blood Specimen Collection 9Surveys and Questionnaires 6Magnetic Resonance Spectroscopy 6Dexamethasone 6Cyclophosphamide 6Prednisone 5Mammography 5Colonoscopy 5Biopsy 5Positron Emission Tomography Computed Tomography 4Magnetic Resonance Imaging 4Lenalidomide 4Biopsy, Fine-Needle 4pembrolizumab 3Tomography, X-Ray Computed 3Surgical Procedures, Operative 3Melphalan 3Liquid Biopsy 3Interviews as Topic 3Exercise 3Diagnostic Tests, Routine 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3weifuchun 2obinutuzumab 2fluciclovine F-18 2daratumumab 2carfilzomib 2Urination 2Preoperative Exercise 2Positron-Emission Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease × Sulfonylurea Compounds × Clear all
NCT07332156 2026-01-14

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

Samsung Medical Center

Completed
21,692 enrolled
Thoracic

Diabetes Mellitus, Type 2, Disease, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡